ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Annexon (ANNX) pipeline and stated timing

Name in SEC filings: Annexon, Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
tanruprubart submission—fourth quarter of 20268-K ·
vonaprument/data readoutStage not statedfourth quarter of 202610-Q ·

Source: ORION, orionbiotechai.com/company/ANNX, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/ANNX

Nearest upcoming stated timing: tanruprubart · NDA/BLA submission · fourth quarter of 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

tanruprubart

Matched

NDA/BLA submissionfourth quarter of 2026

Stage: —

Public float: $244,400,000 · as of · SEC filing

Biologics License Application (BLA) submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026.

8-K · Filed · Last checked

Source details

Accession 0001193125-26-345672

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
tanruprubartSubmissionfourth quarter of 2026
“Biologics License Application (BLA) submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

vonaprumentClinical resultsfourth quarter of 2026
“The Month 15 primary endpoint remains on track for the fourth quarter of 2026.”

Filed · 10-Q

Still within period

As of Oct 19, 2026

tanruprubartSubmission2026
“Next Milestone: BLA submission with initial U.S./European data from FORWARD trial anticipated in 2026.”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

vonaprumentClinical resultsfourth quarter of 2026
“Next Milestone: Topline Phase 3 ARCHER II trial data expected in fourth quarter of 2026.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained program pages

Watch ANNX

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for ANNX. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See ANNX in the calendar · Review labels and methodology

A New Drug Application (NDA) or Biologics License Application (BLA) asks the FDA to approve a drug or biologic for sale.Topline results are the main summary results of a clinical trial, released before the full data.